ProKidney Corp.

PROK

$1.91

-0.52%

N/A-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship ...

Key Metrics of PROK

Snapshot

Latest / TTM · 6 periods

Market Cap

$642.24M

ROCE

-78.3%

EV / EBITDA

-3.55x

-24.2% YoY

FCF Yield

-24.9%

+20.2% YoY

Cash Conversion Cycle

222.8d

Current Ratio

8.36

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$716.48M	$958.08M	$249.30M	$375.54M	$680.90M	$642.24M
Enterprise ValueCompany value including debt and cash adjustments.	$697.26M	$470.22M	$193.06M	$279.66M	$576.40M	$570.90M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	0.00x	3679.70x	645.46x	697.92x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-13.13x	-3.27x	-1.54x	-1.76x	-3.99x	-3.55x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.36	3.39	0.45	0.60	0.72	0.44

Returns + ROCE gauge

ROCE latest

-78.3%

Prev year -54.1%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-204.9%	9.9%	3.2%	6.1%	6.8%	8.8%
ROAProfit generated from total assets.	-136.8%	-20.9%	-8.4%	-13.9%	-20.6%	-34.8%
ROICReturn generated on invested operating capital.	-197.1%	-29.2%	-34.2%	-40.3%	-49.7%	-64.4%
ROCEOperating return on long-term capital used.	-196.9%	-30.2%	-38.3%	-45.4%	-54.1%	-78.3%
Earnings YieldEarnings as a percentage of market value.	-17.5%	-25.6%	-32.3%	-37.0%	-23.0%	-24.3%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-55.49M	$-78.72M	$-124.25M	$-155.85M	$-135.31M	$-159.72M
FCFECash flow available to equity holders after debt flows.	$-55.52M	$-78.97M	$-124.32M	$-155.91M	$-135.34M	$-159.75M
FCF YieldFree cash flow divided by market capitalization.	-17.6%	-18.7%	-113.1%	-94.2%	-45.1%	-24.9%
Income QualityHow well accounting earnings are backed by cash flow.	0.91	0.52	0.66	0.77	0.79	0.96
Capex / OCFShare of operating cash flow spent on capital expenditures.	-10.3%	-2.4%	-38.0%	-23.4%	-12.7%	-13.2%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	11752.0d	460.6d	426.6d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	0.0d	0.0d	203.8d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	11752.0d	460.6d	426.6d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	0.0d	11752.0d	460.6d	222.8d

Snapshot

Latest / TTM: —

Market Cap

$642.24M

ROE

8.8%

FCF Yield

-24.9%

Current Ratio

8.36

Supply Chain of PROK

Upstream / Downstream / Proxies

Upstream

CVS Health Corporation (Clinical Trial Services)NYSE:CVSInRegen / Twin City Bio (acquired by ProKidney in 2019)Thermo Fisher Scientific Inc.NYSE:TMO Danaher Corporation (Cytiva)NYSE:DHRSartorius AGETR:SRTMerck KGaA (Life Science / MilliporeSigma)ETR:MRKBio-Techne CorporationNASDAQ:TECH Charles River Laboratories International Inc.NYSE:CRL Corning IncorporatedNYSE:GLWLonza Group AGSWX:LONN

Downstream

PROACT 1 Clinical Trial Sites (70+ sites across US, Asia, and Latin America)American Association of Kidney Patients (AAKP)CVS Health Corporation (Clinical Trial Services)NYSE:CVSKidney Disease Patient Population (CKD Stage 3b/4 with Type 2 Diabetes)Fresenius Medical Care AG & Co. KGaANYSE:FMS DaVita Inc.NYSE:DVA

Proxies

Royalty Pharma plcNASDAQ:RPRX Mesa Laboratories Inc.NASDAQ:MLAB BioLife Solutions Inc.NASDAQ:BLFS Maravai LifeSciences Holdings Inc.NASDAQ:MRVI

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer